Your browser doesn't support javascript.
loading
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.
Benson, Al B; Venook, Alan P; Adam, Mohamed; Chang, George; Chen, Yi-Jen; Ciombor, Kristen K; Cohen, Stacey A; Cooper, Harry S; Deming, Dustin; Garrido-Laguna, Ignacio; Grem, Jean L; Haste, Paul; Hecht, J Randolph; Hoffe, Sarah; Hunt, Steven; Hussan, Hisham; Johung, Kimberly L; Joseph, Nora; Kirilcuk, Natalie; Krishnamurthi, Smitha; Malla, Midhun; Maratt, Jennifer K; Messersmith, Wells A; Meyerhardt, Jeffrey; Miller, Eric D; Mulcahy, Mary F; Nurkin, Steven; Parikh, Aparna; Patel, Hitendra; Pedersen, Katrina; Saltz, Leonard; Schneider, Charles; Shibata, David; Shogan, Benjamin; Skibber, John M; Sofocleous, Constantinos T; Tavakkoli, Anna; Willett, Christopher G; Wu, Christina; Jones, Frankie; Gurski, Lisa.
Afiliação
  • Benson AB; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
  • Venook AP; UCSF Helen Diller Family Comprehensive Cancer Center.
  • Adam M; UCSF Helen Diller Family Comprehensive Cancer Center.
  • Chang G; The University of Texas MD Anderson Cancer Center.
  • Chen YJ; City of Hope National Medical Center.
  • Ciombor KK; Vanderbilt-Ingram Cancer Center.
  • Cohen SA; Fred Hutchinson Cancer Center.
  • Cooper HS; Fox Chase Cancer Center.
  • Deming D; University of Wisconsin Carbone Cancer Center.
  • Garrido-Laguna I; Huntsman Cancer Institute at the University of Utah.
  • Grem JL; Fred & Pamela Buffett Cancer Center.
  • Haste P; Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
  • Hecht JR; UCLA Jonsson Comprehensive Cancer Center.
  • Hoffe S; Moffitt Cancer Center.
  • Hunt S; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
  • Hussan H; UC Davis Comprehensive Cancer Center.
  • Johung KL; Yale Cancer Center/Smilow Cancer Hospital.
  • Joseph N; University of Michigan Rogel Cancer Center.
  • Kirilcuk N; Stanford Cancer Institute.
  • Krishnamurthi S; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
  • Malla M; O'Neal Comprehensive Cancer Center at UAB.
  • Maratt JK; Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
  • Messersmith WA; University of Colorado Cancer Center.
  • Meyerhardt J; Dana-Farber Cancer Institute.
  • Miller ED; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
  • Mulcahy MF; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
  • Nurkin S; Roswell Park Comprehensive Cancer Center.
  • Parikh A; Mass General Cancer Center.
  • Patel H; UC San Diego Moores Cancer Center.
  • Pedersen K; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
  • Saltz L; Memorial Sloan Kettering Cancer Center.
  • Schneider C; Abramson Cancer Center at the University of Pennsylvania.
  • Shibata D; The University of Tennessee Health Science Center.
  • Shogan B; The UChicago Medicine Comprehensive Cancer Center.
  • Skibber JM; The University of Texas MD Anderson Cancer Center.
  • Sofocleous CT; Memorial Sloan Kettering Cancer Center.
  • Tavakkoli A; UT Southwestern Simmons Comprehensive Cancer Center.
  • Willett CG; Duke Cancer Institute.
  • Wu C; Mayo Clinic Comprehensive Cancer Center.
  • Jones F; National Comprehensive Cancer Network.
  • Gurski L; National Comprehensive Cancer Network.
J Natl Compr Canc Netw ; 22(6): 366-375, 2024 08.
Article em En | MEDLINE | ID: mdl-39151454
ABSTRACT
The determination of an optimal treatment plan for an individual patient with rectal cancer is a complex process. In addition to decisions relating to the intent of rectal cancer surgery (ie, curative or palliative), consideration must also be given to the likely functional results of treatment, including the probability of maintaining or restoring normal bowel function/anal continence and preserving genitourinary functions. Particularly for patients with distal rectal cancer, finding a balance between curative-intent therapy while having minimal impact on quality of life can be challenging. Furthermore, the risk of pelvic recurrence is higher in patients with rectal cancer compared with those with colon cancer, and locally recurrent rectal cancer is associated with a poor prognosis. Careful patient selection and the use of sequenced multimodality therapy following a multidisciplinary approach is recommended. These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Rectal Cancer, including the addition of endoscopic submucosal dissection as an option for early-stage rectal cancer, updates to the total neoadjuvant therapy approach based on the results of recent clinical trials, and the addition of a "watch-and-wait" nonoperative management approach for clinical complete responders to neoadjuvant therapy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Retais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Retais Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article